The FDA Just Changed How Digital Health Devices Get to You—Here's Why It Matters

The Food and Drug Administration (FDA) just launched a groundbreaking pilot program that could dramatically speed up how digital health devices reach patients managing chronic conditions. The Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot allows manufacturers to bypass traditional premarket authorization requirements while collecting real-world performance data.

What Makes This FDA Pilot Different?

Unlike the traditional regulatory pathway that can take years, TEMPO offers a "risk-based enforcement approach" for digital health devices targeting cardio-kidney-metabolic, musculoskeletal, and behavioral health conditions. The pilot represents a collaboration between the FDA's Center for Devices and Radiological Health (CDRH) and the Centers for Medicare and Medicaid Services (CMS) Innovation Center.

"We are piloting an approach to encourage the use of digital technologies that meet people where they are," said FDA Commissioner Marty Makary. "This pilot supports innovative tools and a health care delivery model that could improve care for millions of Americans managing chronic disease."

Which Devices Could Benefit From Faster Access?

The pilot covers a wide range of digital health technologies designed to help patients manage chronic conditions from home. These devices span multiple health areas and complexity levels:

• Low-acuity cardiometabolic conditions: Digital tools for managing prediabetes and early-stage metabolic issues
• Complex cardiometabolic conditions: Advanced monitoring systems for heart failure and related complications
• Musculoskeletal issues: Digital therapeutics and monitoring devices for conditions like back strain and joint problems
• Behavioral health conditions: Apps and devices designed to support mental health management, including depression treatment tools

The FDA plans to select up to ten manufacturers in each of these four clinical areas, with the pilot beginning in January 2026.

How Does This Connect to the Booming Digital Health Market?

This regulatory shift comes as the global digital health market is experiencing explosive growth. The market is expected to reach $573.53 billion by 2030, up from $199.14 billion in 2025, representing a compound annual growth rate of 23.6%. This growth is being driven by widespread adoption of artificial intelligence-powered analytics, wearable sensors, mobile health apps, and remote monitoring systems.

"Digital health technologies are rapidly transforming how people manage chronic conditions, and we want to ensure our regulatory approach keeps pace," said Center for Devices and Radiological Health Director Michelle Tarver. "The TEMPO pilot will allow us to responsibly encourage innovation while collecting real-world evidence that may help us better understand how these devices perform for patients in their everyday lives."

Healthcare providers currently account for the largest end-user share in the digital health market, with hospitals, clinics, and specialty centers rapidly implementing electronic health records, telemedicine solutions, and AI-powered diagnostic tools. By disease segment, diabetes management led the market in 2024 due to its high global prevalence and the critical need for real-time monitoring through connected glucose meters and continuous glucose monitoring systems.

The TEMPO pilot aligns with the FDA's broader "Home as a Health Care Hub" initiative, which aims to bring health and wellness services directly to where people live, work, and play. This approach seeks to improve outcomes and reduce the burden of chronic disease management while fostering access to digital technologies that can be used safely and effectively outside traditional healthcare settings.